Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 16/20 | 0.64 |
| ▸ | NMBR | P28336 | 2/20 | 0.64 |
| ▸ | GLP1R | P43220 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bombesin SCHEMBL29353003 | 0.94 | GRPR (0.70) | GRPRNMBR | |
| SCHEMBL30783571 | 0.89 | GRPR (0.65) | GRPRNMBR | |
| Bombesin SCHEMBL29364598 | 0.87 | GRPR (0.66) | GRPRNMBR | |
| SCHEMBL29565297 | 0.84 | GRPR (0.68) | GRPRNMBRGLP1R | |
| SCHEMBL31738529 | 0.84 | GRPR (0.62) | GRPRNMBRGLP1R | |
| SCHEMBL4344249 | 0.83 | GRPR (0.69) | GRPR | |
| SCHEMBL16508339 | 0.82 | GRPR (0.69) | GRPR | |
| SCHEMBL19102240 | 0.82 | GRPR (0.69) | GRPR | |
| SCHEMBL1413932 | 0.82 | GRPR (0.68) | GRPR | |
| SCHEMBL1413933 | 0.82 | GRPR (0.68) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| CN-110678198-B | Targeting modules to immune cells expressing universal chimeric antigen receptor and their use in the treatment of cancer, infections and autoimmune disorders | 阿文塞勒欧洲有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117164726-A | Targeting module for immune cells expressing universal chimeric antigen receptor and uses thereof | 阿文塞勒欧洲有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230272066-A1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272066-A1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | CD74, HAVCR2, CD4 | GRPR 695/4885NMBR 385/4885GLP1R 2288/4885 |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | GRPR 2596/4885NMBR 1519/4885GLP1R 3793/4885 |
| US-11560426-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders | CD74, HAVCR2, CD4 | GRPR 703/4885NMBR 376/4885GLP1R 2595/4885 |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | CD74, HAVCR2, CD4 | GRPR 695/4885NMBR 385/4885GLP1R 2288/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | GRPR 1943/4885NMBR 1747/4885GLP1R 3651/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | GRPR 9/4885NMBR 224/4885GLP1R 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.